The Technical Analyst
BetterLife Pharma Inc. [BETRF]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
BetterLife Pharma Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
9.47% $0.0952
America/New_York / 3 mai 2024 @ 14:09
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 10.84 mill |
| EPS: | -0.0100 |
| P/E: | -9.52 |
| Earnings Date: | May 28, 2024 |
| SharesOutstanding: | 113.83 mill |
| Avg Daily Volume: | 0.0251 mill |
| RATING 2024-05-03 |
|---|
| C- |
| Strong Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.52 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -9.52 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0100 (-110.45%) $-0.105 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0902 - 0.100 ( +/- 5.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2014-01-31 | Doroudian Ahmad | Sell | 0 | Common Shares |
| 2014-01-31 | Doroudian Ahmad | Buy | 0 | Common Shares |
| 2011-01-31 | Doroudian Ahmad | Sell | 0 | Common Shares |
| 2011-01-31 | Doroudian Ahmad | Buy | 0 | Common Shares |
| 2010-05-25 | Doroudian Ahmad | Buy | 800 000 | Stock Options |
| INSIDER POWER |
|---|
| 0.00 |
| Last 6 transactions |
| Buy: 1 300 000 | Sell: 0 |
Forecast:
15:49 - $0.0940
Live Trading Signals (every 1 min)
Forecast
1: 14:19 - $0.0940
Forecast 2: 15:09 - $0.0920
Forecast 3: 15:49 - $0.0940
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0952 (9.47% ) |
| Volume | 0.0116 mill |
| Avg. Vol. | 0.0251 mill |
| % of Avg. Vol | 46.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BETRF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BETRF
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Latest Press Releases
2024-05-03 18:00:00 - Press Release
Betterlife Announces Intent To Complete private Placement Of Units
Vancouver, british columbia, may 03, 2024 (globe newswire) -- betterlife pharma inc. (“betterlife” or the “company”) (cse: betr / otcqb: betrf / fra: npau), an emerging biotech company focused on the development and commercialization of non-hallucinogenic lsd-based therapeutics for mental disorders, today announced that the company intends to complete a non-brokered private placement offering (the “private placement”) of up to $500,000. the company intends to use the proceeds for the advancement of its lead compound betr-001, a non-hallucinogenic derivative of lsd (lysergic acid diethylamide), and general working capital purposes. the private placement will be issued in units, pursuant to the offering, with each unit comprised of one common share and one common share purchase warrant having a term of two years from the closing date of the offering...
2024-04-15 05:00:00 - Press Release
Betterlife Pharma Inc. To Present At The 2024 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, british columbia--(newsfile corp. - april 15, 2024) - betterlife pharma inc. (cse: betr) (otcqb: betrf), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 bloom burton & co. healthcare investor conference, which will take place on april 16 and 17 at the metro toronto convention centre. dates: tuesday april 16, 2024-wednesday april 17, 2024 time: 8:30 am-5:00 pm et location: metro toronto convention centre, north building 255 front st w toronto, ontario m5v 2w6 dr. dr. ahmad doroudian, chief executive officer, and dr. hooshmand sheshbaradaran, chief operating officer will be speaking at 04:00pm et on april 16th.
2024-03-04 08:00:00 - Press Release
Betterlife's 2-bromo-lsd For Treatment Of Depression Highlighted By Carleton University
Vancouver, british columbia, march 04, 2024 (globe newswire) -- betterlife pharma inc. (“betterlife” or the “company”) (cse: betr / otcqb: betrf / fra: npau), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its development of 2-bromo-lsd was highlighted in carleton university's articled titled “beyond the magic of mushrooms: using psychedelic derivatives to treat depression”. the article discusses the therapeutic potential of 2-bromo-lsd in treating depression. betterlife's betr-001 is currently undergoing ind-enabling studies and projected to enter human trials in 2024.
2024-01-02 08:00:00 - Press Release
Betterlife Announces Closing Of Convertible Debentures For Further Development Of Betr-001
Vancouver, british columbia, jan. 02, 2024 (globe newswire) -- betterlife pharma inc. (“betterlife” or the “company”) (cse: betr / otcqb: betrf / fra: npau), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the closing of $300,000 convertible debentures to further advance the development its lead compound, betr-001. betr-001 is betterlife's proprietary 2-bromo-lsd, a non-hallucinogenic derivative of lysergic acid diethylamide (lsd).
2023-12-18 08:00:00 - Press Release
Betterlife Announces Closing Of A Private Placement
Vancouver, british columbia, dec. 18, 2023 (globe newswire) -- betterlife pharma inc. (“betterlife” or the “company”) (cse: betr / otcqb: betrf / fra: npau), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has closed a non-brokered private placement pursuant to which the company issued 2,000,000 units (“units”) at a price of $0.10 per unit for aggregate gross proceeds of $200,000 (the “offering”). each unit is comprised of one common share and one warrant. each warrant entitles the holder thereof to acquire one common share at an exercise price of $0.10 at any time up to 24 months from the closing of the offering...
Latest News
2024-04-15 05:00:00 - Newsfile Corp
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre. Dates: Tuesday April 16, 2024-Wednesday April 17, 2024 Time: 8:30 AM-5:00 PM ET Location: Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 Dr. Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer will be speaking at 04:00pm ET on April 16th.
2023-06-22 08:00:00 - GlobeNewsWire
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University's Department of Neuroscience (Ottawa, Canada) will present a study titled “A non-hallucinogenic LSD analogue with therapeutic potential in mood disorders” on the anti-depressant and anti-anxiety activity of BetterLife's 2-bromo-LSD (“BETR-001”) at the upcoming IBNS Meeting on June 25-30 at Niagara Falls, Ontario, Canada...
2023-04-25 08:00:00 - GlobeNewsWire
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University's Department of Neuroscience in Ottawa, Canada, will present on the anti-depressant and anti-anxiety activity of BetterLife's 2-bromo-LSD (“BETR-001”) at the upcoming SOBP Conference, being held April 27-29, 2023 at San Diego, California, USA. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (“LSD”) derivative molecule.
2023-04-24 08:00:00 - Newsfile Corp
BetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - BetterLife Pharma (CSE: BETR), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre. Dates: Tuesday April 25, 2023-Wednesday April 26, 2023 Time: 8:30 AM-4:30 PM ET Location: Metro Toronto Convention Centre, North Building 255 Front St W Toronto, Ontario M5V 2W6 Dr. Ahmad Doroudian & Dr. Hooshmand Sheshbaradaran will be speaking at 3:30 PM ET on April 26th.
2023-04-20 08:00:00 - GlobeNewsWire
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the upcoming Bloom Burton Healthcare Investor Conference on Wednesday April 26, 2023 in Toronto, Ontario, Canada.
2023-03-29 09:31:33 - Proactive Investors
BetterLife Pharma says BETR-001 drug candidate featured in Drug Discovery & Development article
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies,” based on BetterLife's lead candidate BETR-001 (2-bromo-LSD) was published by Drug Discovery & Development on March 22, 2023. The emerging biotech company said the Drug Discovery & Development article describes and adds further comments to the positive data and extensive pharmacological characterization of BETR-001 which were published recently in the peer-reviewed journal Cell Reports.
2023-03-14 13:57:09 - Proactive Investors
BetterLife Pharma closes $1.5M private placement
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced the closing of a brokered private placement worth $1.5 million. The company is offering 15 million units at a price of $0.10 per unit, with each unit containing one share and one share purchase warrant.
2023-03-09 09:27:52 - Proactive Investors
Betterlife Pharma's reports positive study findings for lead candidate BETR-001
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) revealed promising findings from a study on its lead candidate BETR-001 (2-bromo-LSD), a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative molecule. The Vancouver-based biotech said the study on BETR-001, titled “A Non-Hallucinogenic LSD Analog with Therapeutic Potential for Mood Disorders” has been published in a peer-reviewed scientific journal publishing research papers called Cell Reports.
2023-03-08 06:43:53 - Proactive Investors
BetterLife Pharma unveils plans for a private placement offering of units
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced plans for a private placement offering of units, comprising of one common share and one common share purchase warrant of the company. Bloom Burton Securities Inc is acting as the sole placement agent for the offering and the number of units to be distributed, the price of each unit and the exercise price of each common share purchase warrant will be determined by negotiation between the company and Bloom Burton in the context of the market with final terms to be determined at the time of pricing.
2023-01-26 09:16:10 - Proactive Investors
BetterLife Pharma hires strategic advisory services firm to support development toward clinical trials of its psychedelic compounds
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has engaged Bloom Burton Securities Inc for strategic advisory services to support its growth and development initiatives toward clinical trials. “We are very excited to be working with Bloom Burton, Canada's leading healthcare investment banking firm,” BetterLife CEO Ahmad Doroudian said in a statement.